29/07/2021 – AB Science announced that results from its Phase 3 AB09004 study on mild to moderate Alzheimer’s disease have been presented at the annual Alzheimer’s Association International Conference (AAIC)
22/07/2021 – AB Science today announced that an abstract reporting results from its Phase 3 AB09004 study on Alzheimer’s disease has been selected for an oral presentation at the annual Alzheimer’s Association International Conference (AAIC)
20/07/2021 – AB Science announces the publication of an article in the world-renowned journal Science that confirms potential of masitinib as a treatment of Covid-19 with anti-viral activity against SARS-CoV-2 and all tested variants of concern
19/07/2021 – AB Science announces the publication of new survival data showing that masitinib extended survival in ALS by 25 months relative to placebo
12/07/2021 – AB Science announces the validation of its Risk Management Plan by the French National Agency (ANSM) in order to restart patient enrollment in France
Replay of the audio transcript in the audio player below: https://www.ab-science.com/wp-content/uploads/2021/07/2021-07-01_AG_AB_Science_du_30_Juin_2021.mp3
01/07/2021 – AB Science announces today the results of the Combined General Shareholders’ Meeting of June 30, 2021